
Nevisense Studies Demonstrate the Ability of the Device to Diagnose Skin Barrier Dysfunction Including Atopic Dermatitis in Children
SciBase Holding AB developer of augmented intelligence-based solutions for skin disorders, has unveiled two new studies on the ability of Nevisense to detect skin barrier dysfunction and Atopic Dermatitis in children.
The first was a study in pediatric patients conducted in collaboration with the University Children’s Hospital Zürich. The study evaluated the capabilities of Nevisense in distinguishing children with Atopic Dermatitis (AD) from those without the skin condition. Atopic Dermatitis is a prevalent global disorder, affecting approximately 20% of children worldwide. There is currently no clinical device available to aid in the diagnosis or assessment of the severity of AD in children. Nevisense is an office-based imaging tool utilizing Electrical Impedance Spectroscopy (EIS), applied as a harmless electrical signal to the skin to diagnose skin conditions. The device uses augmented intelligence (AI) algorithms to differentiate healthy skin from atopic skin. The key findings of the study are that Nevisense has the capability to detect skin barrier dysfunction in children including skin barrier dysfunction in visually unaffected skin. Additionally, the study suggested that Nevisense could potentially predict a child’s likelihood of developing Atopic Dermatitis in the future.
In a second similar study, SciBase partnered with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland. The study evaluated the use Nevisense to measure skin barrier function in human excised skin samples. The device was employed to assess the impact of commercially available detergents on the skin barrier of both mice and human skin samples. The pivotal findings from this study were that EIS emerged as a dependable biomarker and indicator of skin barrier function in both ex vivo (laboratory research) and in vivo (human studies) models. Notably, it displayed higher sensitivity than traditional trans-epidermal water loss (TEWL) measurements. EIS was also correlated with protein biomarkers associated with inflammatory pathways, underscoring its utility in understanding skin barrier health in relation to inflammation. EIS also correlated with the expression of genes related to the skin barrier, providing valuable insights into the genetic underpinnings of skin health.
In combination, the studies show Nevisense’s ability to aid in the early diagnosis of Atopic Dermatitis in children and be used for skin barrier research, with implications for dermatological and cosmetic studies.